Step 1 of 2
These downloadable slides examine the mechanisms of action, clinical evidence, and distinct adverse event profiles of HER2-, TROP2-, and emerging B7-H3–directed antibody–drug conjugates (ADCs) across solid tumors, including breast cancer, non-small-cell lung cancer, gastric/gastroesophageal junction cancer, and small-cell lung cancer. Clinical trial data and prescribing information for approved and investigational ADCs are reviewed, highlighting how differences in antibody targets, linkers, payloads, and treatment regimens influence toxicity risks. Particular emphasis is placed on the prevention, early recognition, grading, and management of interstitial lung disease/pneumonitis, stomatitis, ocular toxicity, neutropenia, diarrhea, and other treatment-related adverse events. Practical strategies for advanced practice providers include baseline risk assessment, patient education, routine monitoring, supportive care, dose modifications, timely specialty referral, and multidisciplinary coordination to guide toxicity management, minimize complications, and support safe treatment delivery.